Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Lycia Therapeutics | South San Francisco | Series D | $75.0M | 2026-06-25 |
| Triveni Bio | Watertown | Series C | $65.0M | 2026-06-17 |
| Convergent Therapeutics | Cambridge | Series A | $40.0M | 2024-09-24 |
| Septerna | San Francisco | Series B | $150.0M | 2023-07-11 |
| NextPoint Therapeutics | Cambridge | Series B | $42.5M | 2024-02-14 |
| Jumbotail | Bangalore | Series D | $120.0M | 2025-06-30 |
| Lyndra Therapeutics | Watertown | Series E | $101.0M | 2023-12-21 |
| Autobahn Therapeutics | San Diego | Series C | $100.0M | 2024-07-24 |
8 rows of the CSV in 5 of its 18 columns.
- The 25 Invus portfolio companies have raised $5.9B in total.
- 2 of them closed their most recent round in the last 12 months, $140.0M combined.
- The largest of those rounds is Lycia Therapeutics' $75.0M Series D, dated June 2026.
- OrbiMed is an investor in 5 of them, more than any other fund.
- Health care is the most common sector, with 15 companies (60%).
- 36% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (33% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
13 of 25| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| Jumbotail | Jumbotail operates a B2B e-commerce marketplace for food and grocery distribution. | Commerce | Bangalore, India | Series D | $120.0M | 2025-06-30 | $298.6M | Nexus Venture Partners, Kalaari Capital, InnoVen Capital +2 | 101 to 250 | 2015 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Convergent Therapeutics | Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer. | Health care | Cambridge, United States | Series A | $40.0M | 2024-09-24 | $130.0M | RA Capital Management, OrbiMed, Invus | 1 to 10 | 2021 |
| Autobahn Therapeutics | Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. | Biotech | San Diego, United States | Series C | $100.0M | 2024-07-24 | $208.7M | Insight Partners, Invus, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| Endeavor BioMedicines | Endeavor BioMedicines develops treatments that target the underlying causes of pulmonary fibrosis. | Biotech | Solana Beach, United States | Series C | $132.5M | 2024-04-24 | $295.5M | Fidelity, Invus, T. Rowe Price +2 | 11 to 50 | 2018 |
| NextPoint Therapeutics | NextPoint Therapeutics develops therapeutics to treat cancer patients as a clinical-stage biotechnology company. | Biotech | Cambridge, United States | Series B | $42.5M | 2024-02-14 | $122.5M | Invus, Leaps by Bayer, Catalio Capital Management +2 | 51 to 100 | 2020 |
| Lyndra Therapeutics | Lyndra Therapeutics creates oral dosage forms that release drugs over the long term. | Biotech | Watertown, United States | Series E | $101.0M | 2023-12-21 | $284.6M | Polaris Partners, Bill & Melinda Gates Foundation, Invus | 51 to 100 | 2015 |
| Booster | Booster runs fleet management and delivers renewable fuels, gasoline, diesel, and biodiesel. | Energy | Seattle, United States | Series D | $125.0M | 2022-05-25 | $213.6M | RRE Ventures, Maveron, Invus +1 | 251 to 500 | 2014 |
| Marlette Funding | Marlette Funding is a financial technology company that serves customers with lending products. | Fintech | Wilmington, United States | Series E | $225.0M | 2022-03-10 | $2.1B | Invus, Healthcare of Ontario Pension Plan (HOOPP) | 501 to 1,000 | 2013 |
| Future Finance | Future Finance is a non-government lender that offers student loans. | Education | Dublin, Ireland | Series D | $25.8M | 2019-07-09 | Goldman Sachs, QED Investors, Invus +2 | 101 to 250 | 2014 | |
| MarkaVIP | MarkaVIP is an invitation-only online shopping community serving the Middle Eastern market. | Commerce | Amman, Jordan | Series B | $10.0M | 2012-04-25 | Invus, Hummingbird Ventures, Prime Ventures +1 | 501 to 1,000 | 2010 |
Table 1. Invus portfolio companies: the 13 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 25.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| 2 | Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
Table 2. Invus portfolio companies: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | New York, United States | 5 | 20% | 1 | Triveni Bio |
| 2 | Polaris Partners | Private equity firm | Boston, United States | 4 | 16% | 1 | Triveni Bio |
| 3 | Blue Owl | Private equity firm | New York, United States | 3 | 12% | 1 | Lycia Therapeutics |
| 4 | RA Capital Management | Startup incubator | Boston, United States | 3 | 12% | ||
| 5 | Fidelity | Investment bank | Boston, United States | 3 | 12% | ||
| 6 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 2 | 8% | 2 | Lycia Therapeutics, Triveni Bio |
| 7 | Catalio Capital Management | Venture capital firm | New York, United States | 2 | 8% | ||
| 8 | Insight Partners | Private equity firm | New York, United States | 2 | 8% | ||
| 9 | Goldman Sachs | Investment bank | New York, United States | 2 | 8% | ||
| 10 | Franklin Templeton | Private equity firm | San Mateo, United States | 1 | 4% | 1 | Lycia Therapeutics |
| 11 | Cormorant Asset Management | Hedge fund | Boston, United States | 1 | 4% | 1 | Triveni Bio |
| 12 | Biotechnology Value Fund | Venture capital firm | San Francisco, United States | 1 | 4% | ||
| 13 | Samsara BioCapital | Private equity firm | Palo Alto, United States | 1 | 4% | ||
| 14 | Arkin Capital | Hedge fund | Herzliya, Israel | 1 | 4% | ||
| 15 | MPM Capital | Private equity firm | Boston, United States | 1 | 4% |
Table 3. Invus portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 15 | 60% | $3.3B |
| Biotech | 12 | 48% | $3.0B |
| Software | 6 | 24% | $297.0M |
| Commerce | 4 | 16% | $298.6M |
| Fintech | 2 | 8% | $2.1B |
| Education | 2 | 8% | |
| Hardware | 2 | 8% | |
| Artificial intelligence | 1 | 4% | $47.0M |
| Energy | 1 | 4% | $213.6M |
Table 4. Invus portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Invus portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 17 | 68% |
| Switzerland | 2 | 8% |
| France | 2 | 8% |
| India | 1 | 4% |
| Ireland | 1 | 4% |
| Jordan | 1 | 4% |
| Canada | 1 | 4% |
Table 6. Invus portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Cambridge | 4 | 16% |
| Watertown | 2 | 8% |
| San Diego | 2 | 8% |
| Boston | 2 | 8% |
| Paris | 2 | 8% |
| South San Francisco | 1 | 4% |
| San Francisco | 1 | 4% |
| Bangalore | 1 | 4% |
| Allschwil | 1 | 4% |
| Basel | 1 | 4% |
| Solana Beach | 1 | 4% |
| Wilmington | 1 | 4% |
Table 7. Invus portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| June 2026 | 2 | 100% | $140.0M |
Table 8. Invus portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 2 | 8% | $140.0M |
| 2025 | 1 | 4% | $120.0M |
| 2024 | 10 | 40% | $950.1M |
| 2023 | 4 | 16% | $363.0M |
| 2022 | 2 | 8% | $350.0M |
| 2021 | 1 | 4% | $1.2M |
Table 9. Invus portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 8% |
| 2020 to 2022 | 7 | 28% |
| 2015 to 2019 | 10 | 40% |
| 2010 to 2014 | 4 | 16% |
| Before 2010 | 2 | 8% |
Table 10. Invus portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 8% |
| 11 to 50 | 8 | 33% |
| 51 to 100 | 7 | 29% |
| 101 to 250 | 3 | 12% |
| 251 to 500 | 2 | 8% |
| 501 to 1,000 | 2 | 8% |
Table 11. Invus portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Invus is recorded as one of its investors. On 16 November 2026 that is 25 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 13 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 25 rows: 2 have no round amount, 0 no city and 4 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Invus portfolio companies are on the list?
- 25, in the file dated 16 November 2026. 2 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 25 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.